Chronic Kidney DiseaseCKiDNCT00327860
Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)
An observational study of Chronic Kidney Disease, run by Johns Hopkins Bloomberg School of Public Health at 2 sites in United States.
Trial summary
The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Heart, Lung and Blood Institute (NHLBI)… Read more about this study
- Who is it for?
- Ages 6 months to 22 years
- Conditions the study is for
- Chronic Kidney Disease
- How many people
- 1,300 participants
- Where
- 2 sitesUnited States
- Study dates
- Oct 2003to Jul 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months to 22 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: The CKiD Study is a multi-center, prospective cohort study of children, adolescents and young adults with a history of mild to moderate impaired kidney function. The study population consist of four cohorts.
Who may be able to join
- Age between 1 and 16 years (before 17th birthday) for Cohorts 1 and 2; age between 6 months and 16 years (before 17th birthday) for Cohort 3; age between 16 to 22 years (before 23rd birthday) for Cohort 4
- Estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min|1.73m2 for Cohort 1 OR an estimated GFR between 45 and 90 ml/min|1.73m2 based on the updated Schwartz formula for Cohort 2; an estimated GFR ≤60 based on the CKiD Under 25 estimating equation (U25eGFR) OR KRT experience (dialysis or transplant) for Cohort 4
- Willingness and ability to provide informed consent and assent
- For Cohort 3, children with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled.
Who cannot join
- Solid organ (other than kidney), bone marrow or stem cell transplantation
- Cancer diagnosis and receiving treatment or within 12 months post completion of treatment
- Ongoing monitoring for cardiotoxic effects of prior chemotherapy or targeted cancer therapies (e.g., anthracyclines, trastuzumab)
- HIV infection with detectable viral load despite current antiretroviral therapy
- Current pregnancy or pregnancy within past twelve months
- Inability to complete major data collection procedures
Show all 12Show fewer
- Not fluent in English or Spanish
- Plans to move out of area of any participating CKiD site (families can be transferred to another CKiD site if the family moves)
- Existing moderate to severe congenital structural heart disease
- Genetic syndromes involving the central nervous system (e.g., Downs syndrome)
- History of severe to profound intellectual disability (i.e., Intelligence Quotient (IQ)<40, significant impairment in adaptive function and/or inability to independently execute self-care skills)
- For cohort 3, children who are expected to receive renal replacement therapy within 6 months of date of enrollment will not be recruited
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
Children's Mercy Kansas City
Kansas City, Missouri, 64108
Bradley Warady, MD, 816-302-3010, bwarady@cmh.edu
Christine Smith, BSN, RN, CCRC, 816-302-3278, casmith@cmh.edu
- Recruiting
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19146
Susan Furth, MD, PhD, 215-590-2449, FurthS@email.chop.edu
Hannah Derwick, MPH, 267-425-1394, DERWICKH@chop.edu
About this study
The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Heart, Lung and Blood Institute (NHLBI) funded a cooperative agreement including two Clinical Coordinating Centers (at Children's Hospital of Philadelphia and at Children's Mercy Hospital in Kansas City), a central biochemistry laboratory (at the University of Minnesota) and a Data Coordinating Center (at Johns Hopkins School of Public Health) to conduct a prospective epidemiological study of children with chronic kidney disease (CKD).
Read the detailed description
Since its inception in 2003, the scientific aims of CKiD have been to determine the risk factors for decline in kidney function and to define how progressive decline in kidney function impacts biomarkers of risk factors for cardiovascular disease; neurocognitive function and behavior; and growth failure and its associated morbidity.
The goals have been extended to understand the impact of childhood CKD on: the risk factors for decline in kidney function in childhood and young adulthood; the development of cardiovascular disease in adolescence and young adulthood; the trajectories of markers of metabolic bone disease and the relationship to cardiovascular endpoints; and the social function, neurocognitive function and emotional well-being of adolescents and young adults and the relationship to successful transfer to adult nephrology care.
- Conditions
- Chronic Kidney Disease
- Medical subject headings
- Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1 | Age between 1 and 16 years (before 17th birthday) and estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min|1.73m2 | |
| Cohort 2 | Age between 1 and 16 years (before 17th birthday), estimated GFR between 45 and 90 ml/min|1.73m2 based on the updated Schwartz formula, and an equal distribution of children with glomerular and non-glomerular causes of disease were enrolled (i.e., 150 within each) and the study placed an upper limit of 60% for the percent of enrolled with non-glomerular disease. | |
| Cohort 3 | Age between 6 months and 16 years (before 17th birthday) with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled. | |
| Cohort 4 | Age between 16 and 22 years (before 23rd birthday) with moderately impaired kidney function as defined by estimated GFR less than 60 ml/min|1.73m2 based on U25eGFR OR individuals who have initiated kidney replacement therapy (dialysis or transplant). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to Kidney Replacement Therapy
The time to Kidney Replacement Therapy (KRT) is assessed as the date of diagnosis to the date of KRT. The exact KRT date is self-reported by the participant and confirmed by medical record abstraction.
Measured: Annually up to 5 years
Secondary outcomes (2)
Decline in Glomerular filtration rate (GFR) ml/min
Define and identify novel and traditional risk factors for the accelerated decline of GFR at regular annual study visits.
Measured: Up to 25 years
Decline in GFR and risk of cardiovascular disease progression
Analyze the association between decline in GFR and risk of progression of cardiovascular disease at regular annual study visits.
Measured: Up to 25 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2006 (estimated)
- Study startOct 2003
- Primary completionJul 2028 (estimated)
- Study completionJul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (207)Papers the sponsor has linked to this study.
- Other trials for Chronic Kidney DiseaseStudies of the same condition, open and under way.
- More trials run by Johns Hopkins Bloomberg School of Public HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Sponsor
- Investigators
- Susan Furth, MD, PhD, Principal investigator, Children's Hospital of PhiladelphiaBradley Warady, MD, Principal investigator, Children's Mercy Kansas CityDerek Ng, PhD, Principal investigator, Johns Hopkins Bloomberg School of Public HealthJesse Seegmiller, PhD, Principal investigator, University of Minnesota
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00327860
- Sponsor's protocol ID
- DK66116
- Other IDs
- U01DK066143, U01DK066174, U24DK066116, U24DK137522, IRB10007880, IRB00011050
- Acronym
- CKiD
- Status last verified
- Apr 2026
- First submitted
- 18 May 2006
- Last updated
- 17 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Woroniecki RP, Ng DK, Limou S, Winkler CA, Reidy KJ, Mitsnefes M, Sampson MG, Wong CS, Warady BA, Furth SL, Kopp JB, Kaskel FJ. Renal and Cardiovascular Morbidities Associated with APOL1 Status among African-American and Non-African-American Children with Focal Segmental Glomerulosclerosis. Front Pediatr. 2016 Nov 17;4:122. doi: 10.3389/fped.2016.00122. eCollection 2016.
PubMed 27900314Schwartz GJ, Wang H, Erway B, Nordin G, Seegmiller J, Lieske JC, Back SE, Miller WG, Eckfeldt JH. Multicenter Laboratory Comparison of Iohexol Measurement. J Appl Lab Med. 2018 Mar;2(5):711-724. doi: 10.1373/jalm.2017.024240.
PubMed 31276084Wong CS, Kogon AJ, Warady BA, Furth SL, Lantos JD, Wilfond BS. Ethical and Policy Considerations for Genomic Testing in Pediatric Research: The Path Toward Disclosing Individual Research Results. Am J Kidney Dis. 2019 Jun;73(6):837-845. doi: 10.1053/j.ajkd.2019.01.020. Epub 2019 Mar 14.
PubMed 30879919Schwartz GJ, Cox C, Seegmiller JC, Maier PS, DiManno D, Furth SL, Warady BA, Munoz A. Recalibration of cystatin C using standardized material in Siemens nephelometers. Pediatr Nephrol. 2020 Feb;35(2):279-285. doi: 10.1007/s00467-019-04389-2. Epub 2019 Nov 3.
PubMed 31680199Thomas E, Klomhaus AM, Laster ML, Furth SL, Warady BA, Salusky IB, Hanudel MR. Associations between anemia and FGF23 in the CKiD study. Pediatr Nephrol. 2024 Mar;39(3):837-847. doi: 10.1007/s00467-023-06160-0. Epub 2023 Sep 26.
PubMed 37752381Sandokji I, Xu Y, Denburg M, Furth S, Abraham AG, Greenberg JH. Current and Novel Biomarkers of Progression Risk in Children with Chronic Kidney Disease. Nephron. 2024;148(1):1-10. doi: 10.1159/000530918. Epub 2023 May 15.
PubMed 37232009Ren X, Chen J, Abraham AG, Xu Y, Siewe A, Warady BA, Kimmel PL, Vasan RS, Rhee EP, Furth SL, Coresh J, Denburg M, Rebholz CM; Chronic Kidney Disease Biomarkers Consortium. Plasma Metabolomics of Dietary Intake of Protein-Rich Foods and Kidney Disease Progression in Children. J Ren Nutr. 2024 Mar;34(2):95-104. doi: 10.1053/j.jrn.2023.10.007. Epub 2023 Nov 8.
PubMed 37944769Lee AM, Xu Y, Hu J, Xiao R, Hooper SR, Hartung EA, Coresh J, Rhee EP, Vasan RS, Kimmel PL, Warady BA, Furth SL, Denburg MR; CKD Biomarkers Consortium. Longitudinal Plasma Metabolome Patterns and Relation to Kidney Function and Proteinuria in Pediatric CKD. Clin J Am Soc Nephrol. 2024 Jul 1;19(7):837-850. doi: 10.2215/CJN.0000000000000463. Epub 2024 May 6.
PubMed 38709558Lee AM, Xu Y, Hooper SR, Abraham AG, Hu J, Xiao R, Matheson MB, Brunson C, Rhee EP, Coresh J, Vasan RS, Schrauben S, Kimmel PL, Warady BA, Furth SL, Hartung EA, Denburg MR; CKD Biomarkers Consortium. Circulating Metabolomic Associations with Neurocognitive Outcomes in Pediatric CKD. Clin J Am Soc Nephrol. 2024 Jan 1;19(1):13-25. doi: 10.2215/CJN.0000000000000318. Epub 2023 Oct 23.
PubMed 37871960Inker LA, Tighiouart H, Adingwupu OM, Ng DK, Estrella MM, Maahs D, Yang W, Froissart M, Mauer M, Kalil R, Torres V, de Borst M, Klintmalm G, Poggio ED, Seegmiller JC, Rossing P, Furth SL, Warady BA, Schwartz GJ, Velez R, Coresh J, Levey AS. Performance of GFR Estimating Equations in Young Adults. Am J Kidney Dis. 2024 Feb;83(2):272-276. doi: 10.1053/j.ajkd.2023.06.008. Epub 2023 Sep 17. No abstract available.
PubMed 37717845Jiang K, Greenberg JH, Abraham A, Xu Y, Schelling JR, Feldman HI, Schrauben SJ, Waikar SS, Shlipak MG, Wettersten N, Coca SG, Vasan RS, Gutierrez OM, Ix JH, Warady BA, Kimmel PL, Bonventre JV, Parikh CR, Mitsnefes MM, Denburg MR, Furth S; CKD Biomarkers Consortium. Associations of Biomarkers of Kidney Tubule Health, Injury, and Inflammation with Left Ventricular Hypertrophy in Children with CKD. Kidney360. 2023 Aug 1;4(8):1039-1047. doi: 10.34067/KID.0000000000000183. Epub 2023 Jun 12.
PubMed 37303083Furth SL, Cole SR, Moxey-Mims M, Kaskel F, Mak R, Schwartz G, Wong C, Munoz A, Warady BA. Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol. 2006 Sep;1(5):1006-15. doi: 10.2215/CJN.01941205. Epub 2006 Jul 19.
PubMed 17699320Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009 Mar;20(3):629-37. doi: 10.1681/ASN.2008030287. Epub 2009 Jan 21.
PubMed 19158356Schwartz GJ, Kwong T, Erway B, Warady B, Sokoll L, Hellerstein S, Dharnidharka V, Furth S, Munoz A. Validation of creatinine assays utilizing HPLC and IDMS traceable standards in sera of children. Pediatr Nephrol. 2009 Jan;24(1):113-9. doi: 10.1007/s00467-008-0957-0. Epub 2008 Sep 4.
PubMed 18769945Abraham AG, Schwartz GJ, Furth S, Warady BA, Munoz A. Longitudinal formulas to estimate GFR in children with CKD. Clin J Am Soc Nephrol. 2009 Nov;4(11):1724-30. doi: 10.2215/CJN.01860309. Epub 2009 Sep 17.
PubMed 19808217
Study at a glance
From the registry record, last updated by the sponsor on 17 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)
- ClinicalTrials.gov ID
- NCT00327860
- Acronym / sponsor ID
- CKiD / DK66116
- Conditions
- Chronic Kidney Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,300 participants (estimated)
- Lead sponsor
- Johns Hopkins Bloomberg School of Public HealthUniversity, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- Oct 2003 (actual)
- Primary completion
- Jul 2028 (estimated)
- Study completion
- Jul 2028 (estimated)
- First posted
- 19 May 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Heart, Lung and Blood Institute (NHLBI) funded a cooperative agreement including two Clinical Coordinating Centers (at Children's Hospital of Philadelphia and at Children's Mercy Hospital in Kansas City), a central biochemistry laboratory (at the University of Minnesota) and a Data Coordinating Center (at Johns Hopkins School of Public Health) to conduct a prospective epidemiological study of children with chronic kidney disease (CKD).
Detailed description
Since its inception in 2003, the scientific aims of CKiD have been to determine the risk factors for decline in kidney function and to define how progressive decline in kidney function impacts biomarkers of risk factors for cardiovascular disease; neurocognitive function and behavior; and growth failure and its associated morbidity.
The goals have been extended to understand the impact of childhood CKD on: the risk factors for decline in kidney function in childhood and young adulthood; the development of cardiovascular disease in adolescence and young adulthood; the trajectories of markers of metabolic bone disease and the relationship to cardiovascular endpoints; and the social function, neurocognitive function and emotional well-being of adolescents and young adults and the relationship to successful transfer to adult nephrology care.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Cohort 1 | – | –Age between 1 and 16 years (before 17th birthday) and estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min|1.73m2 |
| Cohort 2 | – | –Age between 1 and 16 years (before 17th birthday), estimated GFR between 45 and 90 ml/min|1.73m2 based on the updated Schwartz formula, and an equal distribution of children with glomerular and non-glomerular causes of disease were enrolled (i.e., 150 within each) and the study placed an upper limit of 60% for the percent of enrolled with non-glomerular disease. |
| Cohort 3 | – | –Age between 6 months and 16 years (before 17th birthday) with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled. |
| Cohort 4 | – | –Age between 16 and 22 years (before 23rd birthday) with moderately impaired kidney function as defined by estimated GFR less than 60 ml/min|1.73m2 based on U25eGFR OR individuals who have initiated kidney replacement therapy (dialysis or transplant). |
Who may qualify
- Ages
- 6 months to 22 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- The CKiD Study is a multi-center, prospective cohort study of children, adolescents and young adults with a history of mild to moderate impaired kidney function. The study population consist of four cohorts.
Key inclusion criteria (4 listed)
- Age between 1 and 16 years (before 17th birthday) for Cohorts 1 and 2; age between 6 months and 16 years (before 17th birthday) for Cohort 3; age between 16 to 22 years (before 23rd birthday) for Cohort 4
- Estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min|1.73m2 for Cohort 1 OR an estimated GFR between 45 and 90 ml/min|1.73m2 based on the updated Schwartz formula for Cohort 2; an estimated GFR ≤60 based on the CKiD Under 25 estimating equation (U25eGFR) OR KRT experience (dialysis or transplant) for Cohort 4
- Willingness and ability to provide informed consent and assent
- For Cohort 3, children with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled.
Key exclusion criteria (12 listed)
- Solid organ (other than kidney), bone marrow or stem cell transplantation
- Cancer diagnosis and receiving treatment or within 12 months post completion of treatment
- Ongoing monitoring for cardiotoxic effects of prior chemotherapy or targeted cancer therapies (e.g., anthracyclines, trastuzumab)
- HIV infection with detectable viral load despite current antiretroviral therapy
- Current pregnancy or pregnancy within past twelve months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Time to Kidney Replacement Therapy
Time frame: Annually up to 5 years
The time to Kidney Replacement Therapy (KRT) is assessed as the date of diagnosis to the date of KRT. The exact KRT date is self-reported by the participant and confirmed by medical record abstraction.
2 secondary outcomes
Decline in Glomerular filtration rate (GFR) ml/min
Time frame: Up to 25 years
Decline in GFR and risk of cardiovascular disease progression
Time frame: Up to 25 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2026.
- Background: PubMed 27900314Woroniecki RP, Ng DK, Limou S, Winkler CA, Reidy KJ, Mitsnefes M, Sampson MG, Wong CS, Warady BA, Furth SL, Kopp JB, Kaskel FJ. Renal and Cardiovascular Morbidities Associated with APOL1 Status among African-American and Non-African-American Children with Focal Segmental Glomerulosclerosis. Front Pediatr. 2016 Nov 17;4:122. doi: 10.3389/fped.2016.00122. eCollection 2016.
- Background: PubMed 31276084Schwartz GJ, Wang H, Erway B, Nordin G, Seegmiller J, Lieske JC, Back SE, Miller WG, Eckfeldt JH. Multicenter Laboratory Comparison of Iohexol Measurement. J Appl Lab Med. 2018 Mar;2(5):711-724. doi: 10.1373/jalm.2017.024240.
- Background: PubMed 30879919Wong CS, Kogon AJ, Warady BA, Furth SL, Lantos JD, Wilfond BS. Ethical and Policy Considerations for Genomic Testing in Pediatric Research: The Path Toward Disclosing Individual Research Results. Am J Kidney Dis. 2019 Jun;73(6):837-845. doi: 10.1053/j.ajkd.2019.01.020. Epub 2019 Mar 14.
- Background: PubMed 31680199Schwartz GJ, Cox C, Seegmiller JC, Maier PS, DiManno D, Furth SL, Warady BA, Munoz A. Recalibration of cystatin C using standardized material in Siemens nephelometers. Pediatr Nephrol. 2020 Feb;35(2):279-285. doi: 10.1007/s00467-019-04389-2. Epub 2019 Nov 3.
- Background: PubMed 37752381Thomas E, Klomhaus AM, Laster ML, Furth SL, Warady BA, Salusky IB, Hanudel MR. Associations between anemia and FGF23 in the CKiD study. Pediatr Nephrol. 2024 Mar;39(3):837-847. doi: 10.1007/s00467-023-06160-0. Epub 2023 Sep 26.
- Background: PubMed 37232009Sandokji I, Xu Y, Denburg M, Furth S, Abraham AG, Greenberg JH. Current and Novel Biomarkers of Progression Risk in Children with Chronic Kidney Disease. Nephron. 2024;148(1):1-10. doi: 10.1159/000530918. Epub 2023 May 15.
- Background: PubMed 37944769Ren X, Chen J, Abraham AG, Xu Y, Siewe A, Warady BA, Kimmel PL, Vasan RS, Rhee EP, Furth SL, Coresh J, Denburg M, Rebholz CM; Chronic Kidney Disease Biomarkers Consortium. Plasma Metabolomics of Dietary Intake of Protein-Rich Foods and Kidney Disease Progression in Children. J Ren Nutr. 2024 Mar;34(2):95-104. doi: 10.1053/j.jrn.2023.10.007. Epub 2023 Nov 8.
- Background: PubMed 38709558Lee AM, Xu Y, Hu J, Xiao R, Hooper SR, Hartung EA, Coresh J, Rhee EP, Vasan RS, Kimmel PL, Warady BA, Furth SL, Denburg MR; CKD Biomarkers Consortium. Longitudinal Plasma Metabolome Patterns and Relation to Kidney Function and Proteinuria in Pediatric CKD. Clin J Am Soc Nephrol. 2024 Jul 1;19(7):837-850. doi: 10.2215/CJN.0000000000000463. Epub 2024 May 6.
- Background: PubMed 37871960Lee AM, Xu Y, Hooper SR, Abraham AG, Hu J, Xiao R, Matheson MB, Brunson C, Rhee EP, Coresh J, Vasan RS, Schrauben S, Kimmel PL, Warady BA, Furth SL, Hartung EA, Denburg MR; CKD Biomarkers Consortium. Circulating Metabolomic Associations with Neurocognitive Outcomes in Pediatric CKD. Clin J Am Soc Nephrol. 2024 Jan 1;19(1):13-25. doi: 10.2215/CJN.0000000000000318. Epub 2023 Oct 23.
- Background: PubMed 37717845Inker LA, Tighiouart H, Adingwupu OM, Ng DK, Estrella MM, Maahs D, Yang W, Froissart M, Mauer M, Kalil R, Torres V, de Borst M, Klintmalm G, Poggio ED, Seegmiller JC, Rossing P, Furth SL, Warady BA, Schwartz GJ, Velez R, Coresh J, Levey AS. Performance of GFR Estimating Equations in Young Adults. Am J Kidney Dis. 2024 Feb;83(2):272-276. doi: 10.1053/j.ajkd.2023.06.008. Epub 2023 Sep 17. No abstract available.
- Background: PubMed 37303083Jiang K, Greenberg JH, Abraham A, Xu Y, Schelling JR, Feldman HI, Schrauben SJ, Waikar SS, Shlipak MG, Wettersten N, Coca SG, Vasan RS, Gutierrez OM, Ix JH, Warady BA, Kimmel PL, Bonventre JV, Parikh CR, Mitsnefes MM, Denburg MR, Furth S; CKD Biomarkers Consortium. Associations of Biomarkers of Kidney Tubule Health, Injury, and Inflammation with Left Ventricular Hypertrophy in Children with CKD. Kidney360. 2023 Aug 1;4(8):1039-1047. doi: 10.34067/KID.0000000000000183. Epub 2023 Jun 12.
- Background: PubMed 17699320Furth SL, Cole SR, Moxey-Mims M, Kaskel F, Mak R, Schwartz G, Wong C, Munoz A, Warady BA. Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol. 2006 Sep;1(5):1006-15. doi: 10.2215/CJN.01941205. Epub 2006 Jul 19.
- CKiD WebsiteLink provided by the sponsor.
Related trials for Chronic Kidney Disease
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruiting
An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care
Chronic Kidney Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Susan Furth, MD, PhD principal investigator
Children's Hospital of Philadelphia
Bradley Warady, MD principal investigator
Children's Mercy Kansas City
Derek Ng, PhD principal investigator
Johns Hopkins Bloomberg School of Public Health
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Kidney Disease, run by Johns Hopkins Bloomberg School of Public Health at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Susan Furth, MD, PhD (215-590-2449, FurthS@email.chop.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to Kidney Replacement Therapy (time frame: Annually up to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00327860, which also lists 207 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2026.